JGIA
IBRX icon

Jackson Grant Investment Advisers’s ImmunityBio IBRX Stock Holding History

Jackson Grant Investment Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,000
Closed -$71K – 364
2021
Q2 		$71K Hold
5,000
– – 0.03% 171
2021
Q1 		$119K Hold
5,000
– – 0.05% 137
2020
Q4 		$67K Buy
+5,000
New +$48.1K 0.03% 160

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jackson Grant Investment Advisers's IBRX Position: Q3 2021 in Review

Jackson Grant Investment Advisers sold out of ImmunityBio (IBRX) in Q3 2021, closing a stake of 5,000 shares — an estimated $71K sold.

Jackson Grant Investment Advisers first reported a position in IBRX in Q4 2020 and held it in 3 quarters. The position peaked at $119K in Q1 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2021.

  • Jackson Grant Investment Advisers reported no remaining ImmunityBio position as of Q3 2021 after selling out during the quarter.
  • Jackson Grant Investment Advisers sold 5,000 ImmunityBio shares in Q3 2021, an estimated $71K.
  • Jackson Grant Investment Advisers first reported a position in ImmunityBio in Q4 2020 and held it in 3 quarters.
  • Jackson Grant Investment Advisers's ImmunityBio position peaked at $119K in Q1 2021.
  • 126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2021.

Based on Jackson Grant Investment Advisers's 13F filing for Q3 2021, filed 13 Oct 2021.